← All diseases

Disease Atlas / Disease detail

Progressive external ophthalmoplegia with mitochondrial DNA deletion

Provides an easy-to-understand explanation of the symptoms, diagnosis, management, and research challenges of progressive external ophthalmoplegia with mitochondrial DNA deletion.

progressive external ophthalmoplegia with mitochondrial DNA deletions

MONDO:0000090Public QA completeSource-bound · 1

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · 095fa41accbb

Disease category
Progressive external ophthalmoplegia with mitochondrial DNA deletion is a rare neuromuscular disease associated with mitochondrial dysfunction.
Core mechanism
The primary related factor is the deletion of mitochondrial DNA, and in some patients, abnormalities in nuclear genes involved in mitochondrial DNA maintenance may be present in the background.
Main causes · Related factors
Mitochondrial DNA deletion can interfere with oxidative phosphorylation required for cellular energy production, which can affect the function of muscles and organs with high energy demands.
Representative patterns
Typical manifestations include ptosis and restricted eye movements; bilateral external ophthalmoplegia may cause diplopia or difficulty controlling gaze.
Individual differences
Age of onset and severity vary by individual, and clinical presentation may differ depending on the proportion and distribution of mitochondrial DNA deletions, family history, and genetic background.
Diagnosis
Symptoms generally progress slowly, and in some patients, muscle weakness, exercise intolerance, swallowing or respiratory problems, hearing loss, and cardiac abnormalities may also occur.
Management
Diagnosis is based on medical history and neurological/ophthalmological examinations, and is determined by combining mitochondrial DNA testing of blood or muscle with muscle biopsies and genetic testing as necessary.
Treatment/Research Status
Since the distribution of mitochondrial DNA deletions can vary by tissue, it is difficult to rule out the disease with blood tests alone, and test results must be interpreted along with clinical findings.
Evidence Reading
Management is carried out through a collaborative approach involving necessary specialties such as ophthalmology, neurology, genetics, and rehabilitation, while assessing symptoms and organ-specific risks.
Key Precautions
Currently, the focus of treatment is on symptom relief and complication prevention, rather than an established treatment that consistently reverses mitochondrial DNA deletions themselves.

For patients and families

A structured guide for understanding the disease and preparing for clinical conversations.

At a Glance

Progressive external ophthalmoplegia with mitochondrial DNA deletion is a rare neuromuscular disease associated with mitochondrial dysfunction.

Typical manifestations include ptosis and restricted eye movements; bilateral external ophthalmoplegia may cause diplopia or difficulty controlling gaze.

How the Disease Works

The primary related factor is the deletion of mitochondrial DNA, and in some patients, abnormalities in nuclear genes involved in mitochondrial DNA maintenance may be present in the background.

Mitochondrial DNA deletion can interfere with oxidative phosphorylation required for cellular energy production, which can affect the function of muscles and organs with high energy demands.

Patterns Vary by Person

Age of onset and severity vary by individual, and clinical presentation may differ depending on the proportion and distribution of mitochondrial DNA deletions, family history, and genetic background.

Broad framework of diagnosis and management

Symptoms generally progress slowly, and in some patients, muscle weakness, exercise intolerance, swallowing or respiratory problems, hearing loss, and cardiac abnormalities may also occur.

Diagnosis is based on medical history and neurological/ophthalmological examinations, and is determined by combining mitochondrial DNA testing of blood or muscle with muscle biopsies and genetic testing as necessary.

Current stage of treatment

Since the distribution of mitochondrial DNA deletions can vary by tissue, it is difficult to rule out the disease with blood tests alone, and test results must be interpreted along with clinical findings.

Management is carried out through a collaborative approach involving necessary specialties such as ophthalmology, neurology, genetics, and rehabilitation, while assessing symptoms and organ-specific risks.

Currently, the focus of treatment is on symptom relief and complication prevention, rather than an established treatment that consistently reverses mitochondrial DNA deletions themselves.

How to read clinical trials

Follow-up involves checking not only eye movement and vision but also muscle strength, swallowing and breathing, hearing, and cardiac status according to symptoms, and participation in research does not guarantee treatment efficacy or standard care.

Points to verify in clinical encounters

In clinical practice, it is helpful to check the onset and changes in symptoms, diplopia and ptosis, difficulties with movement and eating, family history, current medications, and symptoms related to hearing, respiration, and the heart.

Medical Guide

This material is for educational purposes and is not intended as guidance for individual diagnosis or treatment.

Evidence and sources

A trial registry status does not establish efficacy or regulatory approval.